多参数MRI与T2/FLAIR错配征补充世界卫生组织2021分类诊断IDH突变型1p/19q非共缺失/ATRX突变型星形细胞瘤
回顾性分析101例IDH突变型弥漫性胶质瘤(组织学2-3级,2019-2021年)的术前多参数MRI,由两名不知晓分子诊断的神经放射科医生评估。16例出现T2/FLAIR错配征,均为IDH突变型1p/19q非共缺失/ATRX突变型星形细胞瘤,其中8例3级、8例2级,均无对比增强。9例有足够多参数MRI数据者中,rCBV≥2联合Cho/Cr≥1.5(30 ms TE)或≥1.8(135 ms TE)任一阳性预测3级组织学的敏感度、特异度、阳性预测值、阴性预测值和准确率均为100%。作者认为T2/FLAIR错配征诊断弥漫性星形细胞瘤特异度100%,联合高Cho/Cr和rCBV升高可高准确度预测组织学分级。
要点
- T2/FLAIR错配征见于16/101例IDH突变型弥漫性胶质瘤,均为IDH突变型1p/19q非共缺失/ATRX突变型星形细胞瘤,且均无对比增强。
- 16例错配征病例中8例为3级、8例为2级,错配征本身不能区分2级与3级。
- 9例多参数MRI可分析者中,rCBV≥2联合Cho/Cr≥1.5(30 ms TE)或≥1.8(135 ms TE)任一阳性预测3级组织学的敏感度、特异度、阳性预测值、阴性预测值和准确率均为100%。
核心结论
- T2/FLAIR错配征检测弥漫性星形细胞瘤特异度100%,联合高Cho/Cr与rCBV升高可高准确度预测组织学分级;未来影像方向应探索类似2021中枢神经系统肿瘤分类的结构与多参数影像联合的分层方法。
研究设计与样本
- 回顾性分析2019-2021年101例组织学2-3级IDH突变型弥漫性胶质瘤病例的影像,由两名不知晓分子诊断的神经放射科医生评估,采用T2/FLAIR错配征进行放射表型分型,术前多参数MRI用于分级。
关键影像表现/征象
- 16/101例显示T2/FLAIR错配征,均为组织学证实的IDH突变型1p/19q非共缺失/ATRX突变型星形细胞瘤。
- 16例错配征病例中8例(50%)为3级、8例(50%)为2级,均无对比增强。
诊断标准与关键数值
- 放射学高级别病变的预设截断值:相对脑血容量(rCBV)≥2、胆碱/肌酸比值(Cho/Cr)≥1.5(30 ms回波时间)或Cho/Cr≥1.8(135 ms回波时间)。
- 9例有足够多参数MRI者中,rCBV≥2联合Cho/Cr≥1.5(30 ms TE)或Cho/Cr≥1.8(135 ms TE)任一阳性预测3级组织学的敏感度、特异度、阳性预测值、阴性预测值和准确率均为100%。
临床应用与阅片要点
- T2/FLAIR错配征可作为IDH突变型1p/19q非共缺失/ATRX突变型星形细胞瘤的放射表型标志,本研究中该征象对弥漫性星形细胞瘤特异度100%。
- 对出现错配征的病例,结合rCBV≥2与Cho/Cr≥1.5(30 ms TE)或≥1.8(135 ms TE)任一阳性,可高准确度预测3级组织学。
- 错配征病例均无对比增强,阅片时不应以增强表现作为排除该类型的依据。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
AIM: To investigate whether T2-weighted imaging-fluid-attenuated inversion recovery (T2/FLAIR) mismatch, T2∗ dynamic susceptibility contrast (DSC) perfusion, and magnetic resonance spectroscopy (MRS) correlated with the histological diagnosis and grading of IDH (isocitrate dehydrogenase)-mutant, 1p/19q non-co-deleted/ATRX (alpha-thalassemia mental retardation X-linked)-mutant astrocytoma.
MATERIALS: Imaging of 101 IDH-mutant diffuse glioma cases of histological grades 2-3 (2019-2021) were analysed retrospectively by two neuroradiologists blinded to the molecular diagnosis. T2/FLAIR mismatch sign is used for radio-phenotyping, and pre-biopsy multiparametric MRI images were assessed for grading purposes. Cut-off values pre-determined for radiologically high-grade lesions were relative cerebral blood volume (rCBV) ≥2, choline/creatine ratio (Cho/Cr) ≥1.5 (30 ms echo time [TE]), Cho/Cr ≥1.8 (135 ms TE).
RESULTS: Sixteen of the 101 cases showed T2/FLAIR mismatch, all of which were histogenetically confirmed IDH-mutant 1p/19q non-co-deleted/ATRX mutant astrocytomas; 50% were grade 3 (8/16) and 50% grade 2 (8/16). None showed contrast enhancement. Nine of the 16 had adequate multiparametric MRI for analysis. Any positive value by combining rCBV ≥2 with Cho/Cr ≥1.5 (30 ms TE) or Cho/Cr ≥1.8 (135 ms TE) predicted grade 3 histology with sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of 100%.
CONCLUSION: The T2/FLAIR mismatch sign detected diffuse astrocytomas with 100% specificity. When combined with high Cho/Cr and raised rCBV, this predicted histological grading with high accuracy. The future direction for imaging should explore a similar integrated layered approach of 2021 classification of central nervous system (CNS) tumours combining radio-phenotyping and grading from structural and multiparametric imaging.
引用
- Sawlani V, Jen JP, Patel M, et al. Multiparametric MRI and T2/FLAIR mismatch complements the World Health Organization 2021 classification for the diagnosis of IDH-mutant 1p/19q non-co-deleted/ATRX-mutant astrocytoma. Clin Radiol. 2023. PMID: 38101998. doi:10.1016/j.crad.2023.11.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。